| 11814443 |
Bi-specific fusion proteins |
Ulrik Nielsen, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum +2 more |
2023-11-14 |
|
| 11673970 |
Bi-specific fusion proteins |
Ulrik Nielsen, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum +1 more |
2023-06-13 |
|
| 11141433 |
Therapeutic cell systems and methods for treating cancer and infectious diseases |
Sivan Elloul |
2021-10-12 |
$49,019,000 |
| 10988547 |
Bi-specific fusion proteins |
Ulrik Nielsen, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum +2 more |
2021-04-27 |
|
| 10858450 |
Bi-specific fusion proteins |
Ulrik Nielsen, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum +1 more |
2020-12-08 |
|
| 10407512 |
Bi-specific fusion proteins |
Ulrik Nielsen, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum +2 more |
2019-09-10 |
|
| 9982060 |
Bi-specific fusion proteins |
Ulrik Nielsen, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum +1 more |
2018-05-29 |
$1,621,000 |
| 9968694 |
Compositions and methods for non-invasive imaging |
Daryl C. Drummond, Dmitri B. Kirpotin, Bart S. Hendriks, Samuel V. Agresta, Helen Lee +1 more |
2018-05-15 |
$1,645,000 |
| 9913901 |
Combination therapy for treating HER2-positive cancers |
Victor Moyo, Bart S. Hendriks, Elena Geretti, Joseph G. Reynolds, Christopher W. Espelin |
2018-03-13 |
$1,892,000 |
| 9718892 |
Method of treating myocardial infarction by administering a bi-specific fusion protein |
Ulrik Nielsen, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum +2 more |
2017-08-01 |
$2,737,000 |
| 9610249 |
Dosage and administration for preventing cardiotoxicity in treatment with ERbB2-targeted immunoliposomes comprising anthracycline chemotherapeutic agents |
Joseph G. Reynolds, Kenneth J. Olivier, Jr., Bart S. Hendriks, Stephan Klinz, Elena Geretti |
2017-04-04 |
$5,986,000 |
| 9511155 |
Compositions and methods for non-invasive imaging |
Daryl C. Drummond, Dmitri B. Kirpotin, Bart S. Hendriks, Samuel V. Agresta, Helen Lee +1 more |
2016-12-06 |
$10,603,000 |
| 9238080 |
Bi-specific fusion proteins |
Ulrik Nielsen, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum +2 more |
2016-01-19 |
$10,500,000 |
| 9226966 |
Dosage and administration for preventing cardiotoxicity in treatment with ERBB2-targeted immunoliposomes comprising anthracycline chemotherapeutic agents |
Joseph G. Reynolds, Kenneth J. Olivier, Jr., Bart S. Hendriks, Stephan Klinz, Elena Geretti |
2016-01-05 |
$5,462,000 |
| 8691771 |
Bi-specific fusion proteins for tissue repair |
Ulrik Nielsen, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum +1 more |
2014-04-08 |
$3,044,000 |
| 6998263 |
Methods of preparing and using a viral vector library |
Imre Kovesdi, Duncan McVey, Joseph T. Bruder, Douglas E. Brough |
2006-02-14 |
$1,615,000 |
| 6951755 |
Vectors and methods for gene transfer |
Imre Kovesdi, Douglas E. Brough |
2005-10-04 |
$2,382,000 |
| 6756044 |
Antigenic complexes and methods |
Petrus W. Roelvink, Joseph T. Bruder, Imre Kovesdi |
2004-06-29 |
$2,365,000 |
| 6740525 |
Adenoviral capsid containing chimeric protein IX |
Petrus W. Roelvink, Imre Kovesdi |
2004-05-25 |
$2,640,000 |
| 6649407 |
Targeting adenovirus with use of constrained peptide motifs |
Petrus W. Roelvink, Imre Kovesdi |
2003-11-18 |
$2,876,000 |
| 6576456 |
Chimeric adenovirus fiber protein |
Erik Falck-Pedersen, Petrus W. Roelvink, Joseph T. Bruder, Jason G. D. Gall, Imre Kovesdi |
2003-06-10 |
$2,015,000 |
| 6465253 |
Vectors and methods for gene transfer to cells |
Imre Kovesdi, Douglas E. Brough |
2002-10-15 |
$1,238,000 |
| 6455314 |
Alternatively targeted adenovirus |
Imre Kovesdi, Petrus W. Roelvink, Joseph T. Bruder |
2002-09-24 |
$1,263,000 |
| 6329190 |
Targetting adenovirus with use of constrained peptide motifs |
Petrus W. Roelvink, Imre Kovesdi |
2001-12-11 |
$945,000 |
| 6153435 |
Nucleic acid that encodes a chimeric adenoviral coat protein |
Ronald G. Crystal, Erik Falck-Pedersen, Jason G. D. Gall, Imre Kovesdi |
2000-11-28 |
|